Transcenta Holding Limited Provides Detailed Update on Measures to Address Disclaimer of Opinion in 2025 Annual Report
Key Points for Investors
- Ongoing Efforts to Resolve Disclaimer of Opinion: Transcenta Holding Limited has issued an extensive update on the progress of nine key measures implemented to resolve the Disclaimer of Opinion in its 2025 Annual Report.
- Multiple Business Development and Financing Negotiations: The company is actively engaged in advanced discussions for out-licensing, co-development, and capital raising, some of which have reached contract negotiation stage.
- Significant Cost Reductions Achieved: In the first half of 2026, the Group reduced labor expenses by 28% and operating expenses by 24% compared to the same period in 2025.
- Recent Monetization of Non-Core Assets: The Group reverted two preclinical licensed assets to Eli Lilly for cash consideration of US\$4.0 million, while maintaining its core pipeline assets.
- Indicative Fundraising Target: The company aims to raise up to US\$100 million by year-end, which, if successful, could materially impact its financial position.
- Ongoing Negotiations and Uncertainties: Many plans remain under negotiation, and their successful completion is uncertain.
Detailed Article
Transcenta Holding Limited (HKEX: 6628) has issued a comprehensive update outlining the current status and progress of its strategic measures to address the Disclaimer of Opinion issued in its 2025 Annual Report. This follows the publication of the Annual Report on April 28, 2026. The company has reaffirmed its commitment to enhancing liquidity, strengthening its financial position, and resolving investors’ concerns.
1. Global Development and Commercialization Initiatives
The Group is advancing discussions with several global and regional pharmaceutical companies and investment institutions for the development and commercialization of its lead asset, osemitamab (TST001), particularly targeting Claudin18.2-positive gastric and gastroesophageal junction cancer. Some negotiations have reached the term-sheet or contract stage, pending certain conditions. The aim is to leverage external partnerships and resources to initiate a global Phase 3 trial, which could be transformative if completed, potentially unlocking significant value.
2. Out-Licensing and Fundraising for Other Pipeline Assets
Transcenta is also actively seeking out-licensing, joint development, or collaboration agreements for its other pipeline programs, including blosozumab (TST002), TST003, TST013, TST198, TST801, TST808, and ozekibart. Multiple parties have conducted due diligence, and some negotiations are advanced. Notably, the Group entered into an amendment agreement with Eli Lilly on July 7, 2026, to revert two non-core preclinical assets for US\$4.0 million in cash. The licensing of blosozumab remains intact.
3. Capital Raising and Financing Strategy
The Group is engaged in ongoing discussions with strategic and institutional investors to raise up to US\$100 million by year-end, subject to market conditions and regulatory approvals. This capital would fund the Group’s prioritized R&D programs and strengthen its balance sheet. The ability to secure this funding is a potential share price catalyst.
4. Proprietary Technology Platform Out-Licensing
After a non-exclusive licensing agreement with EirGenix Inc. for the Group’s Highly Intensified Continuous Bioprocessing (HiCB) platform, Transcenta received RMB10 million upfront and an additional RMB7 million milestone payment in May. Further milestones and royalties are possible, and the Group is in parallel discussions with other industry players for licensing its manufacturing technologies.
5. Global Partnerships in Culture Media and Biomanufacturing
The company is collaborating with global and regional cell-culture-media suppliers and industry partners to commercialize its perfusion and fed-batch media technologies, aiming for recurring revenue streams and deeper supply chain integration.
6. Banking Relationships and Debt Management
The Group secured a new RMB43 million credit facility and drew down RMB13 million in new loans after 2025. Since then, it has successfully renewed and extended approximately RMB85 million in bank loans, supporting operations and R&D expenditures.
7. Supplier Payment Extensions
Transcenta has renegotiated payment schedules with key suppliers, thus improving its short-term cash flow and supporting ongoing operations.
8. CDMO Business Expansion
The Group continues to serve existing and seek new customers for its contract development and manufacturing organization (CDMO) services, leveraging its proprietary bioprocessing technologies.
9. Operational Efficiency and Cost Discipline
The company has implemented strict cost controls, achieving significant reductions in labor and operating expenses in the first half of 2026. Strategic reviews of its manufacturing and CDMO models are underway to further optimize capital intensity and cost structure, while maintaining core capabilities.
Summary and Outlook
The Group has made tangible progress in monetizing non-core assets, securing new financing, and implementing cost discipline. However, not all measures have been fully realized as many negotiations are ongoing. The successful completion of these initiatives, especially the targeted fundraising and pipeline partnerships, could have a material impact on Transcenta’s liquidity, R&D pipeline progression, and ultimately its share price. Investors should closely monitor further announcements as the company navigates these critical negotiations.
Important Notes for Shareholders
- Many strategic initiatives are subject to ongoing negotiations and market conditions; their completion could have a significant effect on company valuation.
- Shareholders should be aware that the timing and certainty of the completion of these measures are not guaranteed.
- The company remains committed to resolving the Disclaimer of Opinion and will provide updates as appropriate.
Board Statement
The Board, led by Dr. Xueming Qian, reiterates its commitment to transparency and to taking all necessary steps to restore investor confidence and strengthen the company’s fundamentals.
Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors should refer to official company disclosures and consult professional advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties.
